Figure 2.

Alloreactive CD4⁺ iTregs impair GVL activity against aggressive leukemia. BALB/c mice were lethally irradiated and transplanted with 5 × 10⁶ TCD-BM, 1 × 10⁶ CD4⁺ iTregs, and 1 ×10⁴ luc-A20 cells. Three days later, 0.5 × 10⁶ CD25-depleted Teffs were injected. Recipients were monitored for survival (A), tumor mortality (B) and tumor load (C) for 80 d n = 10/group. BDF1 recipient mice were lethally irradiated (1200cGy) split dose 3 h apart and transplanted with 5 × 10⁶ TCD-BM, 2 × 10⁶ CD4⁺ iTregs, and 5 × 10³ luc-P815 cells. Three days later, 2 × 10⁶ CD25-depleted Teff cells were injected. Recipients were monitor for survival (D) tumor mortality (E) and tumor load (F) for 60 d, n = 15/group. *p < .05; **p < .01; ***p < .001. Error bars indicate the mean of standard error.